Gene expression levels of the insulin-like growth factor family in patients with AMD before and after ranibizumab intravitreal injections

Clin Interv Aging. 2017 Sep 5:12:1401-1408. doi: 10.2147/CIA.S135030. eCollection 2017.

Abstract

Purpose: The present study focused on the assessment of the mRNA levels of the insulin-like growth factor (IGF) family in patients with the exudative form of age-related macular degeneration (AMD) before and after ranibizumab intravitreal injections.

Patients and methods: An analysis of the expression profile of the IGF family of genes in patients with AMD was carried out using the oligonucleotide microarray and quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) methods.

Results: In the peripheral blood mononuclear cells (PBMCs) obtained from AMD group receiving ranibizumab compared to the peripheral blood mononuclear cells from AMD group before ranibizumab treatment using oligonucleotide microarray technique, six statistically significant differentially expressed transcripts related to the IGF family were detected (unpaired t-test, p<0.05, fold change >1.5). Moreover, analysis using the real-time RT-qPCR technique revealed statistically significant differences in the IGF2 and IGF2R mRNA levels (Mann-Whitney U test, p<0.05) between the two groups that were studied. Statistical analyses of both oligonucleotide microarray and real-time RT-qPCR results demonstrated a significant decreased expression only for IGF2 mRNA.

Conclusion: Our results revealed a changed expression of IGF2 mRNA after ranibizumab treatment.

Keywords: IGF family; age-related macular degeneration; mRNA; ranibizumab.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Female
  • Gene Expression
  • Humans
  • Insulin-Like Growth Factor II / biosynthesis*
  • Intravitreal Injections
  • Leukocytes, Mononuclear
  • Macular Degeneration / drug therapy*
  • Male
  • Middle Aged
  • RNA, Messenger / biosynthesis
  • Ranibizumab / therapeutic use*
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • RNA, Messenger
  • Insulin-Like Growth Factor II
  • Ranibizumab